Please use this identifier to cite or link to this item:
Title: BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitorsBRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors
Author: Veeck, Jürgen
Ropero, Santiago
Setién, Fernando
Gonzalez-Suarez, Eva
Osorio, Ana
Benitez, Javier
Herman, James G.
Esteller, Manel
Keywords: Proteïnes supressores de tumors
Malalties de l'ovari
Tumor suppressor protein
Ovary diseases
Issue Date: 10-Oct-2010
Publisher: American Society of Clinical Oncology
Abstract: Recently, Fong et al reported the antitumor activity of the poly(adenosine diphosphate)-ribose polymerase (PARP) inhibitor olaparib (AZD2281; KU-0059436) in patients with BRCA1/BRCA2 germline mutated ovarian cancer. Female BRCA1 and BRCA2 mutation carriers have a significantly elevated lifetime risk of breast and ovarian cancer. BRCA1 and BRCA2 proteins play major roles in DNA double-strand break repair through homologous recombination, and inhibition of DNA single-strand break repair leads to the accumulation of double-strand breaks. These potentially lethal events in homologous recombination-deficient cells could be exploited for therapeutic purposes. The PARP-1 protein is essential for single-strand break repair, and inhibition of PARP leads to persistence of DNA lesions normally repaired by homologous recombination.
Note: Reproducció del document publicat a:
It is part of: Journal of Clinical Oncology, 2010, vol. 28, num. 29, p. e563-e564
Related resource:
ISSN: 0732-183X
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)

Files in This Item:
File Description SizeFormat 
700234.pdf145.3 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.